Zevra Therapeutics, Inc.ZVRANASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank92
3Y CAGR+19.8%
5Y CAGR+38.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+19.8%/yr
vs -0.8%/yr prior
5Y CAGR
+38.7%/yr
Recent deceleration
Acceleration
+20.7pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
5.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $90.36M | -12.4% |
| 2024 | $103.20M | +39.2% |
| 2023 | $74.12M | +41.2% |
| 2022 | $52.50M | +178.4% |
| 2021 | $18.86M | +7.2% |
| 2020 | $17.59M | -41.8% |
| 2019 | $30.23M | -44.3% |
| 2018 | $54.27M | +62.6% |
| 2017 | $33.37M | -3.2% |
| 2016 | $34.47M | - |